organization · Reporting owner
Apeiron Presight Capital Fund II, L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Alto Neuroscience, Inc.
Report date February 06, 2024 · Filed March 06, 2024
Jointly reported with Apeiron Investment Group Ltd., Angermayer Christian
Section 16 reporting ended · disclosed 2024-03-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 251,881 |
Reported balance
After 2024-02-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-02-06 · Conversion · Acquired 251,881 · Balance 251,881 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. |
| Common StockSEC Table I · non-derivative | IndirectBy Apeiron Presight Capital Fund II, L.P.( | 674,658 |
Reported balance
After 2024-02-06 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-02-06 · Conversion · Acquired 674,658 · Balance 674,658 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
| Warrants to Purchase Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-06 · Conversion · Disposed 444,561 · Balance 0 F4: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-06 · Conversion · Disposed 406,072 · Balance 0 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Apeiron Presight Capital Fund II, L.P. | 0 |
Reported balance
After 2024-02-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-06 · Conversion · Disposed 1,063,918 · Balance 0 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Apeiron Presight Capital Fund II, L.P. | 0 |
Reported balance
After 2024-02-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-06 · Conversion · Disposed 416,665 · Balance 0 F5: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.
F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.
F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
F4: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis.
F5: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis.
BIONOMICS LTD/ADR
Report date July 01, 2024 · Filed October 07, 2024
Jointly reported with Apeiron Investment Group Ltd., Angermayer Christian
Section 16 reporting ended · disclosed 2024-10-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Apeiron Presight Capital Fund II, L.P. | 125,996,580 |
Reported balance
After 2024-10-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-10-02 · Sale · Disposed 90,806 · Balance 125,996,580 F1: Includes Ordinary Shares represented by American Depositary Shares. F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Apeiron Presight Capital Fund II, L.P. | 93,469,320 |
Reported balance
After 2024-10-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-10-03 · Sale · Disposed 180,707 · Balance 93,469,320 F1: Includes Ordinary Shares represented by American Depositary Shares. F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Apeiron Presight Capital Fund II, L.P. | 93,369,060 |
Reported balance
After 2024-10-04 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-10-04 · Sale · Disposed 557 · Balance 93,369,060 F1: Includes Ordinary Shares represented by American Depositary Shares. F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Apeiron Investment Group Ltd. | 183,121,441 |
Reported balance
Holding disclosure · report date 2024-07-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 183,121,441 F1: Includes Ordinary Shares represented by American Depositary Shares. F3: The reportable securities are held by Apeiron. Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes Ordinary Shares represented by American Depositary Shares.
F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
F3: The reportable securities are held by Apeiron. Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2024 Filed Oct 7, 2024 18:22 UTC | BIONOMICS LTD/ADR BNOX · Entity 86952 | SaleOrdinary Shares | 557 | $0.28 | $155.96 |
DisclosureSEC source: 0000950170-24-113344 · ownership.xml · nonDerivative · entry 3 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 93,369,060 F1 · security: Includes Ordinary Shares represented by American Depositary Shares. F2 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| October 03, 2024 Filed Oct 7, 2024 18:22 UTC | BIONOMICS LTD/ADR BNOX · Entity 86952 | SaleOrdinary Shares | 180,707 | $0.29 | $52,405.03 |
DisclosureSEC source: 0000950170-24-113344 · ownership.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 93,469,320 F1 · security: Includes Ordinary Shares represented by American Depositary Shares. F2 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| October 02, 2024 Filed Oct 7, 2024 18:22 UTC | BIONOMICS LTD/ADR BNOX · Entity 86952 | SaleOrdinary Shares | 90,806 | $0.33 | $29,965.98 |
DisclosureSEC source: 0000950170-24-113344 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 125,996,580 F1 · security: Includes Ordinary Shares represented by American Depositary Shares. F2 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries B Preferred Stock · Derivative | 416,665 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 6 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 196,299 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F5 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F5 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries A Preferred Stock · Derivative | 1,063,918 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 5 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 478,359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries A Preferred Stock · Derivative | 406,072 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 4 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 182,577 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionWarrants to Purchase Series A Preferred Stock · Derivative | 444,561 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 3 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,304 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F4 · price: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F4 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F4 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionCommon Stock | 674,658 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P.( Disclosed balance after: 674,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionCommon Stock | 251,881 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.